Abeona Therapeutics (NASDAQ:ABEO) Stock Rating Reaffirmed by Cantor Fitzgerald

Abeona Therapeutics (NASDAQ:ABEO)‘s stock had its “overweight” rating reissued by analysts at Cantor Fitzgerald in a research report issued on Tuesday, Benzinga reports. They currently have a $36.00 price target on the biopharmaceutical company’s stock.

Separately, StockNews.com cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday.

Abeona Therapeutics Stock Down 7.0 %

Abeona Therapeutics stock opened at $3.17 on Tuesday. Abeona Therapeutics has a 52 week low of $2.83 and a 52 week high of $9.01. The business’s 50-day moving average price is $7.43 and its 200 day moving average price is $5.65. The firm has a market cap of $86.70 million, a price-to-earnings ratio of -1.23 and a beta of 1.49.

Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.13). Equities analysts expect that Abeona Therapeutics will post -1.83 EPS for the current year.

Hedge Funds Weigh In On Abeona Therapeutics

Several hedge funds have recently bought and sold shares of ABEO. Jump Financial LLC acquired a new position in Abeona Therapeutics in the fourth quarter valued at $199,000. Worth Venture Partners LLC increased its holdings in Abeona Therapeutics by 76.6% in the third quarter. Worth Venture Partners LLC now owns 281,280 shares of the biopharmaceutical company’s stock valued at $1,184,000 after buying an additional 121,969 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in Abeona Therapeutics by 84.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 3,249,994 shares of the biopharmaceutical company’s stock valued at $13,682,000 after buying an additional 1,488,834 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in Abeona Therapeutics in the third quarter valued at approximately $648,000. Finally, AIGH Capital Management LLC boosted its position in shares of Abeona Therapeutics by 77.7% during the third quarter. AIGH Capital Management LLC now owns 1,135,252 shares of the biopharmaceutical company’s stock worth $4,779,000 after buying an additional 496,278 shares during the period. Hedge funds and other institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.